HOME
CAREERS
CONTACT US
KOREAN
ENGLISH
KR
EN
Toggle navigation
COMPANY
ABOUT US
KEY MEMBERS
HISTORY
BOARD OF DIRECTORS
SCIENTIFIC ADVISORY BOARD
SCIENCE
PIPELINE
COLLABORATION
INVESTORS
NOTICE
PRESENTATION
GENERAL MEETING
OF STOCKHOLDERS
INDEPENDENT
AUDITOR'S REPORT
CONTACT IR
MEDIA
NEWS
VIDEO SOURCE
ESG
OVERVIEW
ENVIRONMENTAL
SOCIAL
GOVERNANCE
NEWS
HOME
MEDIA
NEWS
NEWS
All
Press Release
News Update
Quarterly update
Total
80
30
Press Release
NeoImmuneTech Announces First Patient Dosed in Phase 1 Study of NT-I7 (efineptakin alfa) in Adults with Mild COVID-19
2020-11-30
29
Press Release
NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 2 Study of NT-I7 (efineptakin alfa) in combination with PD-L1 checkpoint inhibitor in First-line Non-small Cell Lung Cancer
2020-11-16
28
Press Release
NeoImmuneTech to Present at Upcoming Scientific/Medical Conferences
2020-11-10
27
Press Release
Genexine and NeoImmuneTech Announce Data Release for their Phase 1b/2 Study of GX-I7/NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in patients with Triple-negative Breast Cancer
2020-11-10
26
Press Release
NeoImmuneTech Announces a Second Clinical Collaboration with Roche to Evaluate NT-I7 (efineptakin alfa) in Combination with PD-L1 checkpoint inhibitor in First-line Non-small Cell Lung Cancer
2020-10-21
25
Press Release
NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1b Study of NT-I7 (efineptakin alfa) and Kymriah® (tisagenlecleucel) in Relapsed/Refractory Large B-Cell Lymphoma
2020-08-24
24
Press Release
NeoImmuneTech Announces FDA Approval to Proceed with Second Study of NT-I7 (efineptakin alfa) in Adult COVID-19 Patients
2020-07-27
23
Press Release
NeoImmuneTech Announces Receipt of IND Clearance to Conduct Window-of-Opportunity Trial of NT-I7 (efineptakin alfa) in Patients with Locally Recurrent Squamous Cell Carcinoma of Head and Neck
2020-07-27
22
Press Release
NeoImmuneTech Receives U.S. FDA Clearance of IND Application for Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)
2020-07-20
21
Press Release
NeoImmuneTech Announces Clearance for Investigational New Drug Application of NT-I7 (efineptakin alfa) in Adults with Mild COVID-19
2020-07-15
<<
<
6
7
8
Search